Latest news from Viva In Vitro.
Un estudio impulsa la investigación en nuevos biomarcadores para mejorar el diagnóstico precoz y la medicina de precisión contra la sepsis
Viva In Vitro Diagnostics, en colaboración con INCLIVA y el Hospital Clínico Universitario de Valencia, impulsa un proyecto de investigación en biomarcadores para sepsis centrado en la activación del inflamasoma NLRP3 y otras interleuquinas asociadas. Este estudio multicéntrico analiza la respuesta inmunitaria del paciente para mejorar el diagnóstico precoz, la estratificación clínica y la medicina de precisión en entornos hospitalarios reales.
Viva In Vitro Diagnostics, patrocinador del 9º Encuentro Internacional Código Sepsis
El papel del Código Sepsis en la estratificación inmunológica del paciente crítico
Viva In Vitro appoints Professor Ignacio Martín-Loeches to its Medical Advisory Board, strengthening its clinical leadership in sepsis and biomedical innovation.
Viva In Vitro strengthens its Medical Advisory Board with the appointment of Professor Ignacio Martín-Loeches, an international expert in sepsis and intensive care medicine. This appointment, together with the collaboration with Dr Ricard Ferrer, further consolidates the company’s position as a reference in biomedical innovation, immunological medicine and clinical translation in the field of sepsis.
Toni Vilaplana (Viva in Vitro Diagnostics): vision, challenges and roadmap of a growing Spanish biotech company
Toni Vilaplana, Managing Director of Viva in Vitro Diagnostics, analyses in this full interview the challenges of biotechnology, innovation and growth in Spain.
Viva in Vitro Diagnostics, once again among APTE’s TOP 100 startups
Viva in Vitro Diagnostics, among APTE’s TOP 100 startups in Spain, strengthens its appeal to investors through solid science, clinical validation and European backing.
Viva In Vitro Diagnostics and Vall d’Hebron launch a new research project to enable early diagnosis and stratification of sepsis
Viva In Vitro Diagnostics, a Spanish company specialized in biotechnological innovation and immunology-based medical solutions, has signed a collaboration agreement with the Vall d’Hebron University Hospital and the Vall d’Hebron Research Institute (VHIR) to carry out a clinical study focused on the functional detection of the NLRP3 inflammasome as a biomarker to improve prognosis, immunological stratification, and active monitoring of patients with sepsis.
Building Enduring Capabilities Through a Pioneering NLRP3 Biomarker Program
Using our currently ongoing endeavors on a NLRP3 inflammasome biomarker development as a case study, we examine how confronting complex biotech challenges systematically builds transferable capabilities that extend far beyond the original target.
Subvención concedida para el fomento de solicitudes de patentes en el exterior
La Oficina Española de Patentes y Marcas (OEPM) ha concedido a VIVA In Vitro Diagnostics una subvención dentro del programa de ayudas para el fomento de solicitudes de patentes y modelos de utilidad en el exterior
Dr. Pablo Pelegrín, Founder and Scientific Advisor of Viva In Vitro, among the world’s most influential scientists according to the Highly Cited Researchers ranking
Dr. Pablo Pelegrín, Founder and Scientific Advisor of Viva In Vitro, among the world’s most influential scientists according to the Highly Cited Researchers ranking
NLRP3 Inflammasome: The Missing Link in Sepsis Survival (summary)
At the 29th International Symposium on Infections in the Critically Ill Patient (ISICIP 2025), one of the most anticipated sessions of the meeting was held: “NLRP3 Inflammasome: The Missing Link in Sepsis Survival.”
Viva In Vitro Diagnostics Featured as a Reference Case in ICEX’s Report on the IVD Sector in China
Viva In Vitro Diagnostics has been included as a reference Spanish biotechnology company in the report In Vitro Diagnostic (IVD) Devices in China, published by ICEX Spain Trade & Investment and prepared by the Economic and Commercial Office of Spain in Shanghai.
NLRP3 Inflammasome: The Missing Link in Sepsis Survival
NLRP3 Inflammasome: The Missing Link in Sepsis Survival – This session, held during the 29th International Symposium on Infections in the Critically Ill Patient (ISICIP 2025), was moderated by Dr. Ricard Ferrer Roca (Vall d’Hebron University Hospital) and featured two prominent speakers: Prof. Evangelos Giomarellos (University of Athens) and Prof. Pablo Pelegrín (University of Murcia, IMIB, and co-founder of Viva In Vitro Diagnostics).
Sepsis changes life in hours: interview with Marianne Haverkamp
As part of Sepsis Awareness Month and in collaboration with AseBio, we conclude the series with the essential voice of a patient: Marianne Haverkamp, sepsis survivor.
Early diagnosis and biotechnology: interview with Dr. Pablo Pelegrín
As part of Sepsis Awareness Month and in collaboration with AseBio, we present the vision of Dr. Pablo Pelegrín Vivancos, Full Professor of Immunology and co-founder of Viva In Vitro.
Early diagnosis, biotechnology and sepsis: interview with Dr. Ricard Ferrer
Interview with Dr. Ricard Ferrer, Head of Intensive Care Medicine at Vall d’Hebron University Hospital (Barcelona) and one of the most renowned voices in the field of sepsis.
World Sepsis Day: Biotechnology to Anticipate a Health Emergency
World Sepsis Day: Biotechnology to Anticipate a Health Emergency. Viva In Vitro.
ISICIP 2025 | NLRP3 Inflammasome: The Missing Link in Sepsis Survival
As part of the scientific program of ISICIP 2025, Viva In Vitro Diagnostics is honored to participate in a key symposium: “NLRP3 Inflammasome: The Missing Link in Sepsis Survival”, to be held on October 16 at 11:00 a.m. in Barcelona.
Critical Path Management in Biomedical Startups: A Framework for Early Implementation
Learn how early critical path management helps biomedical startups like Viva In Vitro optimize capital, accelerate timelines, and lead innovation.
How We Secured the EIC Transition: Key Insights from the Inside, Shared During the CDTI Workshop
We were featured as one of the success stories in the national online workshop organized by CDTI and FECYT on the EIC Transition program — one of the most demanding calls in Europe for scaling disruptive technologies from the laboratory to the market.
Viva In Vitro to Be a Gold Sponsor of ISICIP 2025, the Leading International Event on Sepsis and Intensive Care Medicine
The 29th International Symposium on Infections in the Critically Ill Patient (ISICIP), one of the most relevant scientific events worldwide in the field of severe infections and intensive care medicine, will this year count on the official sponsorship of Viva In Vitro as a Gold Sponsor.
Viva In Vitro represents biotech innovation at South Summit 2025
Our Executive President, Joaquín Gómez Moya, was one of the invited speakers at the roundtable “Frictionless Deep Tech: legal, tax, regulatory and public funding keys to scale without limits”, organized by ClarkeModet and moderated by Clara Pombo at South Summit, one of the largest innovation events in Southern Europe.
Viva In Vitro will count on the collaboration of Dr. Ricard Ferrer as an external advisor to its Medical Advisory Board.
Viva In Vitro announces the external collaboration of Dr. Ricard Ferrer Roca with its Medical Advisory Board (MAB) to support the fight against sepsis.
Viva in Vitro attends the 5th edition of the World Sepsis Congress
The 5th World Sepsis Congress, organized by the Global Sepsis Alliance, was a wake-up call: sepsis can no longer take a back seat on the global health agenda.
Biomedical Data Management: A Strategic Perspective
At Viva In Vitro, biomedical data is of essence in our mission to deliver innovative and reliable solutions that improve clinical outcomes for septic patients.
Collaboration with hospitals of Servicio Murciano de Salud and Servicio Andaluz de Salud in research to reduce hospital mortality from sepsis
Collaboration between the Murcian Health Service, the Andalusian Health Service and the Murcian biotechnology company Viva in Vitro in a research project to reduce hospital mortality due to sepsis.
The Biotech Revolution: Navigating Innovation with Purpose in the Age of Disruption
In the rapidly evolving landscape of biotechnology, companies like those recently selected for the EIC Transition are not just pushing scientific boundaries; we are all participating in redefining what it means to be a successful, purpose-driven enterprise in the 21st century.
The European Innovation Council (EIC) selects Viva in Vitro Diagnostics as one of the 40 most disruptive European companies and awards €2.5 million in non-dilutive funding from the EIC Transition programme.
The European Innovation Council (EIC) selects Viva in Vitro Diagnostics as one of the 40 most disruptive European companies and awards €2.5 million in non-dilutive funding from the EIC Transition programme.
Key Trends in Sepsis Treatment for 2025
From Viva in Vitro, in collaboration with Pablo González-Polanco, Product Development Engineer, and Dr. Verónica Cánovas, Biotechnology Development Manager, we have identified the main trends that are transforming the approach to sepsis. Here we share an in-depth analysis of these innovations. Sepsis continues to be one of the leading causes of mortality and morbidity worldwide, affecting both healthcare systems and millions of patients and their families. With nearly 48.9 million cases annually worldwide and 11 million deaths, this condition represents a critical challenge that demands innovative solutions.
Viva in Vitro Diagnostics, s.l. ha sido beneficiario del programa de ayudas del Instituto de Fomento de la Región de Murcia
Viva In Vitro Diagnostics, S.L. ha sido beneficiaria del Programa de Ayudas del Instituto de Fomento de la Región de Murcia (INFO) destinado a incentivar la contratación de servicios de innovación y competitividad por parte de las pymes regionales, cofinanciado por el Fondo Europeo de Desarrollo Regional (FEDER).
Viva in Vitro Diagnostic on RNE’s “Entre Probetas”: Talking about Sepsis and Biotechnological Solutions
On the program “Entre Probetas” on RNE, Radio 5, our Biotechnology Development Manager, Verónica Cánovas, addressed one of the most critical challenges in biomedicine today: sepsis. This exacerbated immune process can endanger the individual it seeks to protect. Join us for a conversation about research, innovative solutions and the future of biotechnology.
Viva In Vitro receives the Research Award from the Isaac Peral Foundation for its innovation in sepsis
Viva in Vitro has been awarded the Research Award at the Isaac Peral Foundation Awards 2024. This recognition highlights our advance in biotechnology with the development of a pioneering device to detect NLRP3 inflammasome activity in patients with sepsis, contributing to the diagnosis and treatment of this serious disease.
New €1.3 million round for Viva in Vitro brings it over €3 million investment to fight sepsis and boost personalized medicine
In less than 3 years, the Spanish biotech company has attracted the confidence of investors and international medical institutions to complete the development of its Viva Sepscare® prototype for the rapid detection and stratification of patients with sepsis. The company intends to soon extend its clinical validation to other fields such as multiple sclerosis and other ailments.
Análisis: Viva In Vitro avanza hacia la estratificación en atención y desarrollo de terapias personalizadas en sepsis, esclerosis múltiple y otras enfermedades inflamatorias o autoinmunes
Viva In Vitro avanza hacia la estratificación en atención y desarrollo de terapias personalizadas en sepsis, esclerosis múltiple y otras enfermedades inflamatorias o autoinmunes
Viva In Vitro incorporates three international references to its Scientific Advisory Committee: Dr. Mihai Netea, Dr. Eduardo López Collazo and Dr. Rebecca Coll.
The Scientific Advisory Committee is composed of Dr. Mihai Netea, as representative of Radboud University Medical Center (The Netherlands), Dr. Eduardo López Collazo, deputy director of Hospital Universitario de la Paz (Spain), and Dr. Rebecca Coll, of Queen’s University Belfast (UK).
Sensible Management of Retribution to Capital in Biotech Startups
In the dynamic realm of biotech startups, the judicious management of capital and the strategic application of retribution to capital techniques are pivotal for fostering growth and securing long-term sustainability.
DeepTech or The Art of Balancing Capital and Innovation: Strategic Considerations for Biotech CEOs on Cost of Equity
In the high-stakes arena of biotechnological and medical devices startups, the CEO’s role transcends the realms of innovation and enters the intricate world of financial strategy.
Strategic Synergies and Prudent Practices: The Path to Capital Efficiency in Biotech
Capital Efficiency is the lifeline that financially sustains innovation and propels growth in the intricate world of biotech startups. Any seasoned CEO has witnessed the transformative power of strategic synergies and prudent practices in steering DeepTech ventures towards impact and success.
Viva in Vitro en Foro Región de Murcia: destino inversor
Nuestra compañía ha sido elegida como uno de los proyectos más innovadores parar representar a nuestro ecosistema empresarial en el “Foro Región de Murcia, destino inversor”, organizado por El Confidencial.
Dr Rebecca Coll (Queen’s University Belfast) joins Viva’s Scientific and Advisory Committee
Dr Rebecca Coll (Queen’s University Belfast) has joined Viva’s Scientific and Advisory Committee, which continues to be strengthened following the addition of Dr Eduardo Lopez Collazo in January.
Viva incorporates Dr. Eduardo López Collazo into its Advisory and Scientific Committee
Dr. Eduardo López Collazo has signed an agreement with Viva In Vitro to become a member of its Advisory and Scientific Committee, thus reinforcing a project that seeks to generate an important impact in the field of inflammasome biomedicine focused on the development of solutions and services for research, pharmaceutical companies and hospitals.
Viva in Vitro is chosen by APTE as one of the TOP 100 Startups 2023
Our company has been recognised as one of the #TOP100 best startups of 2023, according to the Association of Science and Technology Parks of Spain (APTE).
Viva In Vitro: a pioneering company among the 650 startups with ENISA recognition in 2024
Viva in Vitro achieves ENISA certification as an emerging biotechnology company, leader in sepsis research.
La empresa Viva In Vitro Diagnostics, SL, ha sido reconocida con el prestigioso Premio Empresarial CEI Mare Nostrum
La empresa Viva In Vitro Diagnostics, SL, ha sido reconocida con el prestigioso Premio Empresarial CEI Mare Nostrum en la ceremonia de los II Premios
Viva in Vitro Opens New Facilities at the Murcia Science Park
The emerging biomedical company Viva in Vitro has moved from the Murcian Institute of Health Research (IMIB) to its new headquarters, inaugurated today at the Murcia Science Park.
Viva in Vitro amplía su equipo científico atrayendo talento expatriado
Viva in Vitro amplía su equipo científico atrayendo talento expatriado
La biotech Viva in Vitro alcanza los 1,2 millones de euros de inversión para prevenir la sepsis en hospitales de todo el mundo
Surgida como spinoff del Instituto Murciano de Investigación Biosanitaria (IMIB), abre así una nueva etapa en la que se ampliará el equipo científico y de gestión, y
Viva In Vitro receives the Impact Business 2023 recognition as a social and environmental impact initiative.
The Ship2B Foundation has communicated to the biomedical company Viva In Vitro on this February 15.— “After going through the Impact recognition process, the
Noticia en Expansión ‘Start up’ que pasan del laboratorio a la empresa
Viva in Vitro, ‘spin off’ del Hospital Clínico Universitario Virgen de la Arrixaca, la Universidad de Murcia y el instituto mur- ciano de Investigación Biosanitaria,
Joaquín Gómez Moya: “When innovation is based on science, it is more likely to bring benefits to society”
Viva In Vitro Diagnostics CEO considers it essential to create an association of biotechnology companies in the Region.
Hi!
Welcome to our news page. After years of work and dedication to give this project a corporate shape, Pablo Pelegrín, Carlos García-Palenciano, María Fuensanta-Martínez, on
Dr. Pablo Pelegrín received INFO’s recognition for his contribution to the Knowledge Economy
During the Somos Equipo event, regional president Fernando López-Miras recognized the leaders of the regional economic transformation towards a Knowledge Economy in accordance with the